The clinical investigator

, Volume 71, Issue 8, pp 616–619 | Cite as

Visceral leishmaniasis (kala-azar) after a visit to the Mediterranean region

  • J. Rudi
  • P. Racz
  • M. Hörner
  • B. Kommerell
Case Report
Received:
Accepted:

Summary

The case of a 17-year-old patient is presented who became ill 10 months after a holiday visit to Malta. Symptoms included fever peaking daily at 40° C, pancytopenia, and splenomegaly. There was no evidence of bacterial or virological involvement, and probatory treatment with antibiotics followed by corticosteroids was without success. Examination of bone marrow led to the diagnosis of visceral leishmaniasis (kala-azar). A therapy with pentavalent antimony brought rapid improvement in clinical symptoms and led to complete recovery. A short review is presented of the epidemiology, diagnosis, and therapy of visceral leihmaniasis. The aim of this presentation is to remind the attendant physician of the clinical symptoms involved with the possible case of visceral leishmaniasis.

Key words

Visceral leishmaniasis Kala-azar Antimony 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, Teixeira R, Johnson WD (1986) New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 154:1003–1011Google Scholar
  2. 2.
    Badaro R, Falcoff E, Badaro FS, Carvalho EM, PedralSampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandely M, Silvia L, Bina JC, Teixeira R, Falcoff R, Rocha H, Ho JL, Johnson WD (1990) Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 322:16–21Google Scholar
  3. 3.
    Carvalho EM, Teixeira RS, Johnson WD (1981) Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 33:498–502Google Scholar
  4. 4.
    Carvalho EM, Bacellar O, Barral A, Badaro R, Johnson WD (1989) Antigen-specific immunosuppresion in visceral leishmaniasis is cell mediated. J Clin Invest 83:860–864Google Scholar
  5. 5.
    Chance ML (1992) The 6 diseases of WHO: leishmaniasis. Br Med J 283:1245–1247Google Scholar
  6. 6.
    Davidson RN, Croft SL, Scott A, Maim M, Moody AH, Bryceson ADM (1991) Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061–1062Google Scholar
  7. 7.
    Galea P, Goel KM (1990) Visceral leishmaniasis in a Scottish child. Arch Dis Child 65:1269–1270Google Scholar
  8. 8.
    Hoerauf A, Andrade PP, Andrade CR, Solbach W, Rö1linghoff M (1992) Immunoblotting as a valuable tool to differentiate human visceral leishmaniasis from lymphoproliferative disorders and other clinically similar diseases. Res Immunol 143:375–383Google Scholar
  9. 9.
    Jeannel D, Tuppin P, Brucker G, Danis M, Gentilini M (1991) Imported and autochtonous kala-azar in France. Br Med 1303:336–338Google Scholar
  10. 10.
    Kemp M, Theander TG, Handman E, Hey AS, Kurtzhals JA, Hviid L, Sorensen A, Were JO, Koech DK, Kharazmi A (1991) Activation of human T lymphocytes by leishmania lipophosphoglycan. Scand J Immunol 33:219–214Google Scholar
  11. 11.
    Lohmann-Matthes ML, Lüttig B, Hockertz S (1991) Involvement of membrane-associated TNF in killing of Leishmania donovani parasites by macrophages. Behring Inst Mitt 88:125–132Google Scholar
  12. 12.
    Mittal V, Bhatia R, Sehgal S (1991) Serodiagnosis of Indian kala-azar: evaluation of IFA, ELISA and CIEP tests. J Commun Dis 23:131–134Google Scholar
  13. 13.
    Murray HW, Rubin BY, Rothermel CD (1983) Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. J Clin Invest 72:1506–1510Google Scholar
  14. 14.
    Oren R, Schnur LF, Ben Yehuda D, Mayner V, Okon E, Rachmilewitz EA (1984) Visceral leishmaniasis: a difficult diagnosis and unusual causative agent. J Infect Dis 164:746–749Google Scholar
  15. 15.
    Reincke M, Allolio B, Hackenberg E, Cohen S, Winkelmann W, Kaufmann W (1990) In Europa erworbene viszerale Leishmaniose (Kala-azar). Med Klin 85:220–223Google Scholar
  16. 16.
    Solbach W, Röllinghoff M, Kern P (1992) Differentialdiagnose: Leishmaniase. Dtsch Arzteblatt 89A1:2858–2866Google Scholar
  17. 17.
    Wali JP, Aggarwal P, Gupta U, Saluja S, Singh S (1992) Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. J Infect Dis 166:215–216Google Scholar
  18. 18.
    World Health Organization (1984) The leishmaniases. Report of a WHO expert committee. WHO Technical Report Series 701Google Scholar
  19. 19.
    Zijlstra EE, Ali MS, El-Hassan AM, El Toum IA, Satti M, Ghalib HW, Kager PA (1991) Direct agglutination test for diagnosis and sero-epidemiological survey of kala-azar in the Sudan. Trans R Soc Trop Med Hyg 85:474–476Google Scholar
  20. 20.
    Zijlstra EE, Ali MS, El-Hassan AM, El Toum IA, Satti M, Ghalib HW (1992) Clinical aspects of kala-azar in children from the Sudan: a comparison with the disease in adults. J Trop Pediatr 38:17–21Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • J. Rudi
    • 2
    • 1
  • P. Racz
    • 1
  • M. Hörner
    • 2
  • B. Kommerell
    • 2
  1. 1.Abteilung für PathologieBernhard-Nocht-Institut für TropenmedizinHamburg
  2. 2.Abteilung für GastroenterologieMedizinische UniversitätsklinikHeidelbergGermany

Personalised recommendations